A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMLX SEC filings page.
Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Amylyx's numbers show a high-margin, low-capital model whose economics depend on restoring revenue after FY2024's sharp contraction.
In FY2023,$49.3M of net income became only$11.9M of operating cash flow, with conversion at24.2% ; reported profitability already overstated cash generation. By FY2024, operating cash flow was-$167.6M against a net loss of$301.7M , showing the downturn involved substantial cash consumption rather than merely accounting charges.
Gross margin barely moved from
FY2024 liabilities were only
Financial Health Signals
We do not publish a peer-relative financial health score for Amylyx Pharmaceuticals, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Amylyx Pharmaceuticals, Inc. scores 71.38, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.4B against total liabilities of $27.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Amylyx Pharmaceuticals, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Amylyx Pharmaceuticals, Inc.'s EBITDA was -$49.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Amylyx Pharmaceuticals, Inc. reported a net loss of $45.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Amylyx Pharmaceuticals, Inc. earned -$0.38 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Amylyx Pharmaceuticals, Inc. recorded an outflow of $33.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Amylyx Pharmaceuticals, Inc. held $240.1M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Amylyx Pharmaceuticals, Inc.'s quarterly ROE was -6.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.1 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Amylyx Pharmaceuticals, Inc. invested $28.4M in research and development in Q3 2026. This represents an increase of 42.8% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.
Amylyx Pharmaceuticals, Inc. invested $25K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 4.2% from the same quarter a year earlier.
Not reported for Q3 2026.
AMLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0 | $0-100.0% | $0 | $0-100.0% | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $0n/m | $0-100.0% | $0-100.0% | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $0-100.0% | $0n/m | $0-100.0% | N/A |
| R&D Expenses | $28.4M+42.8% | $23.8M-12.7% | $27.6M+24.8% | $21.2M | $19.9M-6.5% | $27.2M+16.6% | $22.1M-39.6% | N/A |
| SG&A Expenses | $21.3M+31.8% | $21.9M+40.2% | $16.2M+3.1% | $15.4M | $16.2M-9.3% | $15.6M-27.7% | $15.7M-72.8% | N/A |
| Operating Income | -$49.7Mn/m | -$45.7Mn/m | -$43.8Mn/m | -$36.6M | -$36.0Mn/m | -$42.9Mn/m | -$37.8Mn/m | N/A |
| EBITDA | -$49.6Mn/m | -$45.6Mn/m | -$43.7Mn/m | N/A | -$35.9Mn/m | -$42.7Mn/m | -$37.6Mn/m | N/A |
| Income Tax | N/A | N/A | N/A | $46K | $0n/m | $0n/m | $0-100.0% | N/A |
| Net Income | -$45.5Mn/m | -$43.4Mn/m | -$41.3Mn/m | -$33.0M | -$34.4Mn/m | -$41.4Mn/m | -$35.9Mn/m | N/A |
| EPS (Basic) | -$0.38n/m | -$0.39n/m | -$0.37n/m | -$0.28n/m | -$0.37n/m | -$0.46n/m | -$0.42n/m | -$0.54-871.4% |
| EPS (Diluted) | -$0.38n/m | -$0.39n/m | -$0.37n/m | -$0.28n/m | -$0.37n/m | -$0.46n/m | -$0.42n/m | -$0.54-871.4% |
| Diluted Shares (Avg) | 119M+27.4% | 111M+24.7% | 111M+29.0% | N/A | 93M+37.1% | 89M+31.0% | 86M+26.3% | N/A |
Not reported in any period shown, so not listed: Interest Expense.
AMLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $786.8M+116.9% | $264.6M+36.0% | $293.6M+33.7% | $332.6M+71.8% | $362.7M+44.7% | $194.6M-41.4% | $219.7M-47.4% | $193.6M-62.6% |
| Current Assets | $778.9M+120.4% | $256.3M+37.2% | $285.0M+31.9% | $323.7M+70.9% | $353.4M+44.1% | $186.9M-42.8% | $216.1M-47.4% | $189.4M-59.2% |
| Cash & Equivalents | $240.1M+6.6% | $49.3M-15.1% | $229.1M+283.4% | $226.7M+192.9% | $225.2M+213.4% | $58.1M-22.6% | $59.8M-65.0% | $77.4M-54.5% |
| Short-Term Investments | $528.0M+344.4% | $201.4M+64.1% | $50.6M-64.9% | $90.3M-8.9% | $118.8M-26.9% | $122.7M-47.7% | $144.3M-28.8% | $99.1M-50.7% |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Accounts Receivable | N/A | N/A | N/A | $88K-80.3% | $132K-92.4% | $103K-97.5% | $300K-98.5% | $447K-98.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $33.1M+7.5% | $25.4M-5.0% | $20.4M+12.0% | $27.4M-5.1% | $30.7M-43.6% | $26.7M-62.3% | $18.3M-80.4% | $28.9M-65.6% |
| Current Liabilities | $29.0M+12.6% | $21.1M-1.3% | $16.0M-11.0% | $22.7M-20.1% | $25.8M-52.2% | $21.4M-69.4% | $17.9M-80.4% | $28.4M-65.4% |
| Non-Current Liabilities | $4.0M-19.0% | $4.2M-19.8% | $4.5M+1268.8% | $4.7M+914.7% | $5.0M+732.6% | $5.3M+586.1% | $327K-76.3% | $463K-76.6% |
| Total Equity | $753.7M+127.0% | $239.2M+42.5% | $273.2M+35.6% | $305.3M+85.3% | $332.0M+69.2% | $167.9M-35.8% | $201.4M-37.9% | $164.8M-62.0% |
| Retained Earnings | -$881.6Mn/m | -$836.1Mn/m | -$792.7Mn/m | -$751.4Mn/m | -$718.4Mn/m | -$684.0Mn/m | -$642.6Mn/m | -$606.7Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
AMLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.7Mn/m | -$31.4Mn/m | -$36.9Mn/m | -$27.9Mn/m | -$30.4Mn/m | -$25.2Mn/m | -$39.8Mn/m | -$59.0M-535.5% |
| Depreciation & Amortization | $33K-72.5% | $43K-69.5% | $98K-37.2% | $108K-32.5% | $120K-45.7% | $141K-32.2% | $156K-50.5% | $160K-46.8% |
| Stock-Based Compensation | $10.4M+46.6% | $8.3M+13.2% | $6.1M-10.4% | N/A | $7.1M+4.0% | $7.3M-23.2% | $6.8M-31.1% | N/A |
| Capital Expenditures | $25K+4.2% | N/A | N/A | $86K+330.0% | $24K | $17K-80.9% | $11K-83.6% | $20K-94.4% |
| Free Cash Flow | -$33.7Mn/m | N/A | N/A | -$28.0M | -$30.4M | -$25.3Mn/m | -$39.8Mn/m | N/A |
| Investing Cash Flow | -$325.7M-6319.7% | -$149.8M-751.5% | $36.3Mn/m | $29.5M-54.7% | $5.2M-86.5% | $23.0Mn/m | -$43.7M-5430.8% | $65.0M+210.5% |
| Financing Cash Flow | $550.2M+187.1% | $1.5Mn/m | $3.2M-95.1% | -$208K-289.1% | $191.6M+239407.5% | -$31K-214.8% | $65.7M+50023.7% | $110K-52.2% |
| Dividends Paid | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
AMLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -6.0%+4.3pp | -18.2%+6.5pp | -15.1%+2.7pp | -10.8% | -10.4%+26.7pp | -24.7%+3.1pp | -17.8%+18.8pp | N/A |
| Return on Assets | -5.8%+3.7pp | -16.4%+4.9pp | -14.1%+2.3pp | -9.9% | -9.5%+19.5pp | -21.3%+0.6pp | -16.4%+12.1pp | N/A |
| Current Ratio | 26.81+13.1x | 12.12+3.4x | 17.85+5.8x | 14.27+7.6x | 13.70+9.2x | 8.72+4.1x | 12.05+7.6x | 6.67+1.0x |
| Liabilities-to-Equity | 0.040.0x | 0.11-0.1x | 0.070.0x | 0.09-0.1x | 0.09-0.2x | 0.16-0.1x | 0.09-0.2x | 0.180.0x |
| Asset Turnover | N/A | N/A | N/A | 0.00 | 0.000.0x | 0.000.0x | 0.00-0.2x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. AMLX | FY2025 | $0 | -$144.7M | N/A | $3.4B | — |
| Liquidia Corporation LQDA | FY2025 | $158.3M | -$68.9M | -43.5% | $5.1B | 64/100 |
| Xeris Biopharma Holdings, Inc. XERS | FY2025 | $291.8M | $554K | 0.2% | $3.1B | 45/100 |
| Hims & Hers Health, Inc. HIMS | FY2025 | $2.3B | $128.4M | 5.5% | $4.0B | 49/100 |
| Bausch Health Companies Inc BHC | FY2025 | $10.3B | $157.0M | 1.5% | $3.3B | 50/100 |
| HUTCHMED (China) Limited HCM | FY2025 | $548.5M | $456.9M | 83.3% | $2.4B | 42/100 |
Where Amylyx Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Amylyx Pharmaceuticals, Inc. (AMLX) revenue declined by 100.0% year-over-year, from $87.4M to $0 in fiscal year 2025.
No, Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M in fiscal year 2025.
Amylyx Pharmaceuticals, Inc. (AMLX) had EBITDA of -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Amylyx Pharmaceuticals, Inc. (AMLX) had $332.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Amylyx Pharmaceuticals, Inc. (AMLX) invested $138K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Amylyx Pharmaceuticals, Inc. (AMLX) invested $90.4M in research and development during fiscal year 2025.
Amylyx Pharmaceuticals, Inc. (AMLX) had a current ratio of 14.27 as of fiscal year 2025, which is generally considered healthy.
Amylyx Pharmaceuticals, Inc. (AMLX) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Amylyx Pharmaceuticals, Inc. (AMLX) had a return on assets of -43.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Amylyx Pharmaceuticals, Inc. (AMLX) held $317.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $123.3M over that year. Dividing the one by the other, the reported balance equals about 31 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Amylyx Pharmaceuticals, Inc. (AMLX) has an Altman Z-Score of 71.38, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Amylyx Pharmaceuticals, Inc. (AMLX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.